GIMBHI’s daily mental health update — 4/20/26

💊 White House orders faster FDA reviews for psychedelic mental health treatments (Nicholas Jacobus, Pharmaceutical Commerce) — 04/20/26
TL;DR: Trump signed an executive order fast-tracking FDA review of psychedelic therapies for PTSD, anxiety, and depression, initially focused on U.S. veterans’ mental health.

💰 Digital health startups raised $4B in Q1 2026, fueled by 12 megadeals (Katie Adams, MedCity News) — 04/06/26
TL;DR: Per Rock Health, digital health funding hit $4B across 110 deals in Q1 2026, with WHOOP’s $575M Series G leading the quarter.

🤝 Teva, Direct Relief, NAFC extend funding for mental health care at free clinics (Teva Pharmaceuticals) — 04/14/26
TL;DR: Community Routes program granted $75K each to 11 free clinics across Alabama, Mississippi, and Texas to expand mental health services after reaching 57,000+ people in 2025.

😴 Exit 156 Capital backs NightWare’s Series C to scale PTSD nightmare therapy (NightWare, Inc., GlobeNewswire) — 04/14/26
TL;DR: Exit 156 Capital invested in NightWare’s Series C at a $10M pre-money valuation to expand its FDA-cleared digital therapeutic for PTSD-related nightmares across the VA and first responder markets.

🧬 Hormones and mental health: bridging neuroendocrinology and psychiatry (Philip R. Muskin, Psychiatric Times) — 04/20/26
TL;DR: Special report explores how sex hormones and prolactin shape brain circuits, offering new biomarkers and treatment strategies for eating disorders, psychosis, and depression.